Bayer, Raptor reel in endorsements from EMA for new therapies

The European Medicines Agency's experts have backed approval for two drugs that have already gained green lights for the U.S. market. Bayer won the EU agency's endorsement for Stivarga, a targeted drug for colorectal cancer, which is partnered with Onyx Pharmaceuticals ($ONXX). Raptor Pharmaceuticals garnered the EMA's blessing for marketing its therapy Procysbi for the most common form of a rare genetic disease called cystinosis. As usual, the European Commission will decide within months whether to take the advice of the EMA. Stivarga news | Procysbi news